These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15969880)

  • 1. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
    Guest JF; Clegg JP; Davie AM; McCloskey E
    Curr Med Res Opin; 2005 May; 21(5):805-15. PubMed ID: 15969880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.
    DesHarnais Castel L; Bajwa K; Markle JP; Timbie JW; Zacker C; Schulman KA
    Support Care Cancer; 2001 Oct; 9(7):545-51. PubMed ID: 11680835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
    Reed SD; Radeva JI; Glendenning GA; Coleman RE; Schulman KA
    Am J Clin Oncol; 2005 Feb; 28(1):8-16. PubMed ID: 15685028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
    Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
    Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
    Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
    Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
    Hillner BE; Weeks JC; Desch CE; Smith TJ
    J Clin Oncol; 2000 Jan; 18(1):72-9. PubMed ID: 10623695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
    Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
    Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of seasonal allergic conjunctivitis in the UK.
    Guest JF; Clegg JP; Smith AF
    Curr Med Res Opin; 2006 Sep; 22(9):1777-85. PubMed ID: 16968581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
    Schivazappa C; Berto P; Baldini E; Barni S; Dauria G; Cortesi E
    Recenti Prog Med; 2008 Jan; 99(1):27-31. PubMed ID: 18389868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.